当前位置： SCI文献检索 > Cochrane Database of Systematic Reviews期刊下所有文献 > Methotrexate as a steroid sparing agent for asthma in adults.

Methotrexate as a steroid sparing agent for asthma in adults.

Abstract：

BACKGROUND:Sustained oral corticosteroid use can lead to complications, so there is interest in identifying agents that can reduce oral steroid use in people with asthma. Methotrexate has attracted attention as a possible steroid sparing agent in patients with chronic oral steroid dependent asthma. OBJECTIVES:The objective of this review was to assess the effects of adding methotrexate to oral corticosteroids in adults with stable asthma who are dependent on oral corticosteroids. SEARCH STRATEGY:The Cochrane Airways Group trials register and reference lists of identified articles were searched. SELECTION CRITERIA:Randomised trials of the addition of methotrexate compared with placebo in adult steroid dependent asthmatics. Duration of therapy needed to be at least 12 weeks. DATA COLLECTION AND ANALYSIS:Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information. MAIN RESULTS:Ten trials involving a total of 185 people were included. Study design and quality, corticosteroid dosages and outcomes varied widely. There was a reduction in oral corticosteroid dose favouring methotrexate in parallel trials (weighted mean difference -4.1 mg per day, 95% confidence interval -6.8 to -1.3) and also in cross-over trials (weighted mean difference -2.9 mg per day, 95% confidence interval -5.9 to -0.2). There was no difference between methotrexate and placebo for forced expiratory volume in one minute (weighted mean difference 0.12 litre, 95% confidence interval -0.21 to 0.45). Hepatotoxicity was a common adverse effect with methotrexate compared to placebo (odds ratio 6.9, 95% confidence interval 3.1 to 15.5). REVIEWER'S CONCLUSIONS:Methotrexate may have a small steroid sparing effect in adults with asthma who are dependent on oral corticosteroids. However, the overall reduction in daily steroid use is probably not large enough to reduce steroid-induced adverse effects. This small potential to reduce the impact of steroid side-effects is probably insufficient to offset the adverse effects of methotrexate.

journal_name

Cochrane Database Syst Rev

journal_title

The Cochrane database of systematic reviews

authors

Davies H,Olson L,Gibson P

doi

10.1002/14651858.CD000391

keywords:

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

CD000391

issue

issn

1469-493X

pii

CD000391

pub_type

杂志文章,评审

在线工具

Methotrexate as a steroid sparing agent for asthma in adults.